派格生物通过港交所聆讯:投后估值40亿,60岁实控人徐敏为美国籍

瑞财经
28 Apr

瑞财经 王敏4月25日,据港交所官网,派格生物医药(苏州)股份有限公司(以下简称“派格生物”)通过聆讯,准备在港交所上市,中金公司为独家保荐人。值得注意的是,2024年11月13日,派格生物第二次向港交所递表,冲刺港股IPO;同年2月份,派格生物曾向港交所递表,但最后无疾而终。而在此之前,派格生物还曾准备在科创板上市,计划募资25.38亿元,但在2022年4月IPO被终止,后转战到了港交所。据...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10